amersham cydye cy5 mono reactive dye  (GE Healthcare)

Journal: Heliyon

Article Title: The study of antiviral drugs targeting SARS-CoV-2 nucleocapsid and spike proteins through large-scale compound repurposing

doi: 10.1016/j.heliyon.2021.e06387

Figure Lengend Snippet: Identification of small molecule inhibitors binding to SARS-CoV-2 full-length N protein and S-RBD protein by molecular chip technology. (A) Schematic of the binding procedure for detecting small molecule and protein based on small molecule microarray. (B) The positive compound that binds to Cy5-labeled N protein ( left ). A control experiment was carried out without N protein ( right ). The 71 candidates of N protein-interacting compounds were identified by comparing the signals from the two microarrays. (C) The positive compound that binds to Cy5-labeled S-RBD protein ( left ). A control experiment was carried out without S-RBD protein ( right ). The 71 candidates of S-RBD protein-interacting compounds were identified by comparing the signals from the two microarrays. (D) Representative the 15 protein spots with the largest fold change of N protein. (E) Representative the top 15 compounds for S-RBD protein-interacting. Scan the Cy5 signals at 635 nm +, in the presence of Cy5-S-RBD protein; −, in the presence of Cy5 alone.

Article Snippet: The protein was labeled with Cy5 using a CyDye Protein Labeling Cy5™ Mono-Reactive Dye Pack [ ] (GE Healthcare, Little Chalfont, UK).

Techniques: Binding Assay, Microarray, Labeling